| Popis: |
BACKGROUND With the increasingly abundant of cancer treatment, the emergence of multidisciplinary team (MDT) will provide patients with personalized treatment options. In recent years, artificial intelligence has developed rapidly in the medical field. And there is a tendency to replace traditional diagnosis and treatment gradually. IBM Watson for Oncology (WFO) has been proven in breast cancer and lung cancer, but the research on gastric cancer is rarely so far. OBJECTIVE Compared the concordance of WFO with that of MDT, and we try to investigate the patients' prognosis between them. METHODS This study retrospectively analyzed the eligible cases (N=235) of MDT with gastric cancer who received the corresponding treatment and obtained follow-up. Then doctors input the information of all cases into WFO manually, and the results was compared with the treatment programs by MDT. If the treatment program of MDT is classified as “recommended” or “considered”, we define the results as concordant. All patients were divided into concordant group and non-concordant group according to whether the treatment program of WFO and MDT were concordant. The prognostic analysis of the two groups was analyzed. RESULTS The overall concordance of WFO and MDT was 54.5% (128/235) in all 235 cases included in the study. Subgroup analysis found that patients with human epidermal growth factor receptor 2 (HER2)-positive were less likely to be concordant than patients with HER2-negative (P=0.019). Age, Eastern Cooperative Oncology Group performance status, differentiation type and clinical stage was not found to affect concordance. In all patients, the survival time of concordant patients were significantly better than that of non-concordant patients (P CONCLUSIONS Treatment recommendations made by WFO and MDT were mostly concordant for gastric cancer cases. If they can include the local treatment programs, the concordance will be significantly improved. The HER2 status of gastric cancer have a significant effect on concordance. Generally speaking, patients with concordant treatment programs had quite better survival than non-concordant patients. |
